Weave’s new Strategic Advisory Board brings together senior leaders from Boehringer Ingelheim, Takeda, Gilead, Serrado Capital, and Stanford University. These leaders shape how the industry operates today, and where it must go tomorrow. Their guidance will keep Weave building technology that earns trust, not just power. The board marks the next step in Weave’s momentum, following a $20 million Series A round and a strategic partnership with Parexel.
Press release
Weave Bio Establishes Inaugural Strategic Advisory Board
Related news
Press release
Weave Bio Appoints Krates Ng as Chief Technology Officer to Power Enterprise-Scale Regulatory AI
Press release
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
Press release
Two Former FDA Leaders Join Weave Bio’s Strategic Advisory Board
Press release